DeepMed Research

1,2-Distearoyllecithin

Generic Name: 1,2-Distearoyllecithin

Brand Names: Lumason

Drug Type: Small Molecule

Chemical Formula: C_₄₄H_₈₈NO_₈P

CAS Number: 4539-70-2

Unique Ingredient Identifier: EAG959U971

Clinical Trials

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

Phase 1

Not yet recruiting

Conditions: Alzheimer Disease, Early Onset

Interventions: Device: Neuronavigation-guided single-element focused ultrasound transducer
Drug: Lumason
Other: Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
Radiation: Positron Emission Tomography (PET)
Drug: Amyvid
Drug: MK-6240
Drug: Dotarem
Diagnostic Test: Blood draw
Device: UR5e
Diagnostic Test: Urine test

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-11

Lead Sponsor: Columbia University

Target Recruit Count: 6

Registration Number: NCT06600880

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Lumason® Infusion vs. Bolus Administrations

Phase 3

Not yet recruiting

Conditions: Heart Diseases

Interventions: Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Drug: Lumason

First Posted Date: 2024-05-06

Last Posted Date: 2024-05-06

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 106

Registration Number: NCT06400004

Locations: 🇺🇸
Piedmont Heart Institute, Atlanta, Georgia, United States
🇺🇸
Oregon Health and Sciences University, Portland, Oregon, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Phase 1

Not yet recruiting

Conditions: Glioblastoma Multiforme
Glioma
Brain Tumor
Neoplasms
Glioblastoma
Neoplasms, Nerve Tissue

First Posted Date: 2024-03-26

Last Posted Date: 2024-03-26

Lead Sponsor: NaviFUS Corporation

Target Recruit Count: 10

Registration Number: NCT06329570

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).

Early Phase 1

Recruiting

Conditions: Breast Cancer
Contrast Enhanced Ultrasound

Interventions: Drug: Lumason

First Posted Date: 2023-07-24

Last Posted Date: 2024-12-05

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 20

Registration Number: NCT05957042

Locations: 🇺🇸
Penn State Health College of Medicine, Hershey, Pennsylvania, United States

Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema

Phase 1

Completed

Conditions: Lymphedema Arm

Interventions: Drug: Optison
Drug: Definity
Drug: Lumason

First Posted Date: 2022-11-14

Last Posted Date: 2024-08-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 10

Registration Number: NCT05613946

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Applying pGz in Mitochondrial Disease

Phase 1

Recruiting

Conditions: Mitochondrial Myopathies
Mitochondrial Diseases

Interventions: Diagnostic Test: Cardiopulmonary Exercise Testing
Device: pGz Bed
Device: Exercise Pedal
Drug: Lumason® contrast agent
Device: Gentle Jogger

First Posted Date: 2022-10-06

Last Posted Date: 2024-12-27

Lead Sponsor: Children's Hospital of Philadelphia

Target Recruit Count: 90

Registration Number: NCT05569122

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Contrast Ultrasound for Pediatric Trauma - Comparative Evaluation (CAPTURE Study)

Phase 1

Active, not recruiting

Conditions: Abdominal Injury

Interventions: Drug: Lumason

First Posted Date: 2021-01-22

Last Posted Date: 2024-05-09

Lead Sponsor: David Mooney

Target Recruit Count: 68

Registration Number: NCT04718441

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

and more 2 locations

Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE

Phase 4

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Lumason

First Posted Date: 2020-09-30

Last Posted Date: 2023-11-02

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 26

Registration Number: NCT04569799

Locations: 🇺🇸
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States

Comparison of Three Methods for Early Detection of Breast Cancer

Early Phase 1

Completed

Conditions: Proliferative Breast Disease

Interventions: Diagnostic Test: Contrast Enhanced imaging
Drug: Lumason

First Posted Date: 2019-05-17

Last Posted Date: 2022-01-10

Lead Sponsor: Mayo Clinic

Target Recruit Count: 3

Registration Number: NCT03954015

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)

Phase 1

Not yet recruiting

Conditions: Vesico-Ureteral Reflux

Interventions: Drug: Lumason

First Posted Date: 2018-08-31

Last Posted Date: 2023-08-31

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 70

Registration Number: NCT03653702

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy